You are here

  • Home
  • Archive
  • Volume 80, Issue 10
  • Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’

Article Text

Article menu
Download PDFPDF
Correspondence
Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’

https://doi.org/10.1136/annrheumdis-2021-220736

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • JV and JW contributed equally.

    • Contributors JV: study conception, drafting the manuscript and data analysis. KM-M:, study conception and manuscript editing. JW, TL and BZ: sample processing, data generation and analysis. IH: patient recruitment. LZ: study conception, manuscript editing and funding. Q-SM: study conception, data analysis, manuscript editing and funding.

    • Funding This publication presents independent research funded by the NIH/NIAMS R01AR063611 (Q-SM), Henry Ford Immunology Program T71017 (Q-SM) and T71016 (LZ).

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.